Top

Published in:

01-02-2012 | Epidemiology

Hormone therapy use and mammographic density in postmenopausal Norwegian women

Authors: Elisabeth Couto, Samera Azeem Qureshi, Solveig Hofvind, Marit Hilsen, Hildegunn Aase, Per Skaane, Lars Vatten, Giske Ursin

Published in: Breast Cancer Research and Treatment | Issue 1/2012

Abstract

While studies have shown that use of postmenopausal hormone therapy with estrogen and progestogen (EPT) increases mammographic density, aspects of this association remain unclear. We examined whether mammographic density differed by type of hormone therapy (HT) used, dose, duration of use, time since last use, and whether the effects are modified by age and body mass index (BMI). Using a cross-sectional design, we recruited 2,424 postmenopausal women aged 50–69 years participating in the Norwegian Breast Cancer Screening Program. Mammographic density was assessed with a computer-assisted method, and we estimated mean absolute and percent mammographic density through multiple linear regression, and adjusting for possible confounders. Mammographic density was higher among current HT users (percent density: 22.6%; 95% CI: 22.1–23.2%) than among former (17.7%; 17.2–18.2%) or never users (16.3%; 15.7–16.8%). The highest density was seen in current EPT users of high-dose norethisterone acetate (NETA) regimens who had a percent density of 26.2% (24.3–28.1%). Results differed when considering the combined effect of age and BMI. The effect of EPT on mammographic density was modified by age and BMI, with no apparent association among the youngest women (aged 50–55) with the highest BMI (BMI ≥ 26). A higher mammographic density was found in EPT users compared to never HT users, particularly in women using high-dose NETA regimens. Age and BMI modified the association between EPT use and mammographic density.

Available only for authorised users

Boyd NF, Martin LJ, Bronskill M, Yaffe MJ, Duric N, Minkin S (2010) Breast tissue composition and susceptibility to breast cancer. J Natl Cancer Inst 102(16):1224–1237PubMedCrossRef

McCormack VA, dos Santos Silva I (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15(6):1159–1169PubMedCrossRef

Buist DS, Porter PL, Lehman C, Taplin SH, White E (2004) Factors contributing to mammography failure in women aged 40–49 years. J Natl Cancer Inst 96(19):1432–1440PubMedCrossRef

Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster V (1996) Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA 276(1):33–38PubMedCrossRef

Boyd N, Martin L, Stone J, Little L, Minkin S, Yaffe M (2002) A longitudinal study of the effects of menopause on mammographic features. Cancer Epidemiol Biomarkers Prev 11(10 Pt 1):1048–1053PubMed

McCormack VA, Perry NM, Vinnicombe SJ, Dos Santos Silva I (2010) Changes and tracking of mammographic density in relation to Pike’s model of breast tissue aging: a UK longitudinal study. Int J Cancer 127(2):452–461PubMed

Bremnes Y, Ursin G, Bjurstam N, Lund E, Gram IT (2007) Different types of postmenopausal hormone therapy and mammographic density in Norwegian women. Int J Cancer 120(4):880–884PubMedCrossRef

Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G (2003) Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 95(1):30–37PubMedCrossRef

Maskarinec G, Pagano I, Lurie G, Kolonel LN (2006) A longitudinal investigation of mammographic density: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 15(4):732–739PubMedCrossRef

10.

McTiernan A, Chlebowski RT, Martin C, Peck JD, Aragaki A, Pisano ED, Wang CY, Johnson KC, Manson JE, Wallace RB et al (2009) Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women’s health initiative randomized trial. J Clin Oncol 27(36):6135–6143PubMedCrossRef

11.

McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski RT, Pisano ED, Wang CY, Brunner RL, Johnson KC, Manson JE et al (2005) Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women’s Health Initiative randomized trial. J Natl Cancer Inst 97(18):1366–1376PubMedCrossRef

12.

Persson I, Thurfjell E, Holmberg L (1997) Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density. J Clin Oncol 15(10):3201–3207PubMed

13.

Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S (2001) Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 285(2):171–176PubMedCrossRef

14.

Sala E, Warren R, McCann J, Duffy S, Luben R, Day N (2000) High-risk mammographic parenchymal patterns, hormone replacement therapy and other risk factors: a case-control study. Int J Epidemiol 29(4):629–636PubMedCrossRef

15.

Stuedal A, Ma H, Bjorndal H, Ursin G (2009) Postmenopausal hormone therapy with estradiol and norethisterone acetate and mammographic density: findings from a cross-sectional study among Norwegian women. Climacteric 12(3):248–258PubMedCrossRef

16.

Titus-Ernstoff L, Tosteson AN, Kasales C, Weiss J, Goodrich M, Hatch EE, Carney PA (2006) Breast cancer risk factors in relation to breast density (United States). Cancer Causes Control 17(10):1281–1290PubMedCrossRef

17.

van Duijnhoven FJ, Peeters PH, Warren RM, Bingham SA, van Noord PA, Monninkhof EM, Grobbee DE, van Gils CH (2007) Postmenopausal hormone therapy and changes in mammographic density. J Clin Oncol 25(11):1323–1328PubMedCrossRef

18.

Aiello EJ, Buist DS, White E (2006) Do breast cancer risk factors modify the association between hormone therapy and mammographic breast density? (United States). Cancer Causes Control 17(10):1227–1235PubMedCrossRef

19.

Lee SA, Ross RK, Pike MC (2005) An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 92(11):2049–2058PubMedCrossRef

20.

Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350(9084):1047–1059

21.

Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362(9382):419–427PubMedCrossRef

22.

Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women’s health initiative randomized trial. JAMA 289(24):3243–3253PubMedCrossRef

23.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the women’s health initiative randomized controlled trial. JAMA 288(3):321–333PubMedCrossRef

24.

Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA (2000) Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes Control 11(7):653–662PubMedCrossRef

25.

Ursin G, Astrahan MA, Salane M, Parisky YR, Pearce JG, Daniels JR, Pike MC, Spicer DV (1998) The detection of changes in mammographic densities. Cancer Epidemiol Biomarkers Prev 7(1):43–47PubMed

26.

Altman DG (1991) Practical statistics for medical research. Chapman and Hall, London

27.

Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE et al (2006) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295(14):1647–1657PubMedCrossRef

28.

Buist DS, Anderson ML, Reed SD, Aiello Bowles EJ, Fitzgibbons ED, Gandara JC, Seger D, Newton KM (2009) Short-term hormone therapy suspension and mammography recall: a randomized trial. Ann Intern Med 150(11):752–765PubMed

29.

Weaver K, Kataoka M, Murray J, Muir B, Anderson E, Warren R, Warsi I, Highnam R, Glasier A (2008) Does a short cessation of HRT decrease mammographic density? Maturitas 59(4):315–322PubMedCrossRef

30.

Harvey JA, Pinkerton JV, Herman CR (1997) Short-term cessation of hormone replacement therapy and improvement of mammographic specificity. J Natl Cancer Inst 89(21):1623–1625PubMedCrossRef

31.

Kelemen LE, Pankratz VS, Sellers TA, Brandt KR, Wang A, Janney C, Fredericksen ZS, Cerhan JR, Vachon CM (2008) Age-specific trends in mammographic density: the Minnesota breast cancer family study. Am J Epidemiol 167(9):1027–1036PubMedCrossRef

32.

Li T, Sun L, Miller N, Nicklee T, Woo J, Hulse-Smith L, Tsao MS, Khokha R, Martin L, Boyd N (2005) The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev 14(2):343–349PubMedCrossRef

33.

Boyd NF, Martin LJ, Li Q, Sun L, Chiarelli AM, Hislop G, Yaffe MJ, Minkin S (2006) Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15(5):961–966PubMedCrossRef

34.

Byrne C, Ursin G, Martin CF, Peck JD, Cole EB, Heiss G, McTiernan A, Zeng D, Chlebowski RT, Lane DS, Manson JE, Wactawski-Wende J, Yasmeen S, Boyd NF, Yaffe MJ, Pisano ED (2010) Change in mammographic density with estrogen and progestin therapy: a measure of breast cancer risk in the Women’s Health Initiative. In: AACR. Washington

35.

Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, Forbes JF, Warren RM (2011) Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst 103(9):744–752PubMedCrossRef

Title: Hormone therapy use and mammographic density in postmenopausal Norwegian women
Authors: Elisabeth Couto
Samera Azeem Qureshi
Solveig Hofvind
Marit Hilsen
Hildegunn Aase
Per Skaane
Lars Vatten
Giske Ursin
Publication date: 01-02-2012
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-011-1810-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Impact of a telephone-based physical activity intervention upon exercise behaviors and fitness in cancer survivors enrolled in a cooperative group setting

The association between mammographic density measures and aspirin or other NSAID use

Genomic profiling of mitochondrion-rich breast carcinoma: chromosomal changes may be relevant for mitochondria accumulation and tumour biology

Bloody nipple discharge is a predictor of breast cancer risk: a meta-analysis

Women’s features and inter-/intra-rater agreement on mammographic density assessment in full-field digital mammograms (DDM-SPAIN)

Epstein–Barr virus is seldom found in mammary epithelium of breast cancer tissue using in situ molecular methods

Keynote webinar | Spotlight on antibody–drug conjugates in cancer